MedPath

Post treatment CIN: Randomised Controlled Trial using hrHPV-testing for prediction of recurrent or residual disease.

Completed
Conditions
Post treatment CIN, cytology and hrHPV testing.
Registration Number
NL-OMON26752
Lead Sponsor
Department of Obstetrics and Gynaecology, Erasmus University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, the Netherlands. phone:+31-10-4633381Email: t.helmerhorst@erasmusmc.nlFax: +31-10-4633315
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
204
Inclusion Criteria

Women indicated to be treated for high-grade CIN lesions.

Exclusion Criteria

1. Previous treatment for high-grade CIN;

2. An immune compromised state;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath